|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.300 USD | +3.60% |
|
+3.60% | +27.78% |
| 05-13 | Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026 | |
| 05-13 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Main competitors
| P/E (Y) | Price to Book (Y) | PEG (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
| 11.79x | - | -0.03x | - | - | - | - | 185M | ||
| 35.2x | 21.24x | 0.71x | 12.84x | 26.1x | 26.96x | 0.57% | 1,077B | ||
| 27.22x | 6.85x | -1.79x | 6.26x | 17.02x | 18.8x | 2.1% | 613B | ||
| 32.17x | -922.25x | 0.14x | 7.47x | 15.29x | 15.69x | 2.73% | 448B | ||
| 17.9x | 6.65x | 1.05x | 4.45x | 10.94x | 12.35x | 2.98% | 332B | ||
| 23.72x | 5.52x | 1.08x | 4.94x | 14x | 14.72x | 1.76% | 293B | ||
| 21.69x | 6.52x | -244.35x | 5.59x | 13.51x | 14.79x | 2.83% | 286B | ||
| 14.19x | 6.09x | -5.3x | 5.21x | 10.72x | 12.52x | 3.54% | 215B | ||
| 23.3x | 17.37x | 2.88x | 6.21x | 10.84x | 14.21x | 2.81% | 193B | ||
| -45.82x | 8.69x | 0.32x | 5.53x | 30.47x | 61.52x | 2.54% | 159B | ||
| 11.36x | 1.58x | 0.2x | 3.03x | 7.37x | 8.57x | 7.21% | 138B | ||
| 28.09x | 5.64x | 1.98x | 8.58x | 19.36x | 20.15x | -.--% | 125B | ||
| 11.27x | 4.99x | 0.24x | 3.09x | 8.25x | 8.96x | 4.37% | 117B | ||
| 12.56x | 4.59x | 1.06x | 2.76x | 8.11x | 9.16x | 3.53% | 104B | ||
| 11.17x | 1.2x | 2.22x | 2.14x | 6.9x | 7.84x | 5.67% | 103B | ||
| 24.05x | 5.45x | 1.4x | 8.16x | 15.42x | 16.13x | 1.84% | 75.68B | ||
| 19.99x | 1.63x | -0.12x | 1.71x | 8.11x | 13.62x | 0.49% | 52.66B | ||
| 41.41x | 1.09x | 60.5x | 2.58x | 9.49x | 26.28x | 4.02% | 49.71B | ||
| 34.6x | 4.68x | 1.8x | 7.67x | 25.59x | 28.18x | 0.56% | 47.27B | ||
| Average | 18.73x | -45.14x | -9.26x | 5.46x | 14.30x | 18.36x | 2.75% | 233.13B | |
| Weighted average by Cap. | 23.44x | -83.79x | -14.94x | 7.29x | 17.04x | 19.54x | 2.26% |
- Stock Market
- Stocks
- PLX Stock
- Sector Protalix BioTherapeutics, Inc.
- Sector valuations
Select your edition
All financial news and data tailored to specific country editions
















